Nizatidine disposition in subjects with normal and impaired renal function

George R. Aronoff, Richard F. Bergstrom, Ronald J. Bopp, Rebecca S. Sloan, John Callaghan

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

To test the hypothesis that renal insufficiency alters nizatidine disposition, we determined the pharmacokinetics of nizatidine and its major metabolite after a single oral dose in normal volunteers and patients with various degrees of renal dysfunction, after a single intravenous dose in normal volunteers and patients with severe renal failure and during hemodialysis. After intravenous administration the elimination half-life increased from 1.5 ± 0.2 hours in normal volunteers to 6.9 ± 3.3 hours in patients with renal failure. The plasma clearance decreased from 0.59 ± 0.07 L/kg/hr in normal volunteers to 0.14 ± 0.02 L/kg/hr in patients with renal failure. Nizatidine bioavailability was nearly 100% in normal volunteers but decreased to 75% in patients with renal failure. The volume of distribution was 1.3 ± 0.1 L/kg in normal volunteers and was not different in patients with renal failure. Nizatidine protein binding was about 30% in normal and uremic plasma. The drug was not substantially removed by hemodialysis. Patients with creatinine clearances less than 50 ml/min/1.73 m2 should receive 150 mg nizatidine once each evening. Patients with creatinine clearances less than 20 ml/min/1.73 m2 should receive 150 mg nizatidine every other night.

Original languageEnglish
Pages (from-to)688-695
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume43
Issue number6
StatePublished - Jun 1988

Fingerprint

Nizatidine
Renal Insufficiency
Kidney
Healthy Volunteers
Renal Dialysis
Creatinine
Protein Binding
Intravenous Administration
Biological Availability
Half-Life
Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Aronoff, G. R., Bergstrom, R. F., Bopp, R. J., Sloan, R. S., & Callaghan, J. (1988). Nizatidine disposition in subjects with normal and impaired renal function. Clinical Pharmacology and Therapeutics, 43(6), 688-695.

Nizatidine disposition in subjects with normal and impaired renal function. / Aronoff, George R.; Bergstrom, Richard F.; Bopp, Ronald J.; Sloan, Rebecca S.; Callaghan, John.

In: Clinical Pharmacology and Therapeutics, Vol. 43, No. 6, 06.1988, p. 688-695.

Research output: Contribution to journalArticle

Aronoff, GR, Bergstrom, RF, Bopp, RJ, Sloan, RS & Callaghan, J 1988, 'Nizatidine disposition in subjects with normal and impaired renal function', Clinical Pharmacology and Therapeutics, vol. 43, no. 6, pp. 688-695.
Aronoff, George R. ; Bergstrom, Richard F. ; Bopp, Ronald J. ; Sloan, Rebecca S. ; Callaghan, John. / Nizatidine disposition in subjects with normal and impaired renal function. In: Clinical Pharmacology and Therapeutics. 1988 ; Vol. 43, No. 6. pp. 688-695.
@article{eb04ac01d4db4f51810df85fc840b8d3,
title = "Nizatidine disposition in subjects with normal and impaired renal function",
abstract = "To test the hypothesis that renal insufficiency alters nizatidine disposition, we determined the pharmacokinetics of nizatidine and its major metabolite after a single oral dose in normal volunteers and patients with various degrees of renal dysfunction, after a single intravenous dose in normal volunteers and patients with severe renal failure and during hemodialysis. After intravenous administration the elimination half-life increased from 1.5 ± 0.2 hours in normal volunteers to 6.9 ± 3.3 hours in patients with renal failure. The plasma clearance decreased from 0.59 ± 0.07 L/kg/hr in normal volunteers to 0.14 ± 0.02 L/kg/hr in patients with renal failure. Nizatidine bioavailability was nearly 100{\%} in normal volunteers but decreased to 75{\%} in patients with renal failure. The volume of distribution was 1.3 ± 0.1 L/kg in normal volunteers and was not different in patients with renal failure. Nizatidine protein binding was about 30{\%} in normal and uremic plasma. The drug was not substantially removed by hemodialysis. Patients with creatinine clearances less than 50 ml/min/1.73 m2 should receive 150 mg nizatidine once each evening. Patients with creatinine clearances less than 20 ml/min/1.73 m2 should receive 150 mg nizatidine every other night.",
author = "Aronoff, {George R.} and Bergstrom, {Richard F.} and Bopp, {Ronald J.} and Sloan, {Rebecca S.} and John Callaghan",
year = "1988",
month = "6",
language = "English",
volume = "43",
pages = "688--695",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Nizatidine disposition in subjects with normal and impaired renal function

AU - Aronoff, George R.

AU - Bergstrom, Richard F.

AU - Bopp, Ronald J.

AU - Sloan, Rebecca S.

AU - Callaghan, John

PY - 1988/6

Y1 - 1988/6

N2 - To test the hypothesis that renal insufficiency alters nizatidine disposition, we determined the pharmacokinetics of nizatidine and its major metabolite after a single oral dose in normal volunteers and patients with various degrees of renal dysfunction, after a single intravenous dose in normal volunteers and patients with severe renal failure and during hemodialysis. After intravenous administration the elimination half-life increased from 1.5 ± 0.2 hours in normal volunteers to 6.9 ± 3.3 hours in patients with renal failure. The plasma clearance decreased from 0.59 ± 0.07 L/kg/hr in normal volunteers to 0.14 ± 0.02 L/kg/hr in patients with renal failure. Nizatidine bioavailability was nearly 100% in normal volunteers but decreased to 75% in patients with renal failure. The volume of distribution was 1.3 ± 0.1 L/kg in normal volunteers and was not different in patients with renal failure. Nizatidine protein binding was about 30% in normal and uremic plasma. The drug was not substantially removed by hemodialysis. Patients with creatinine clearances less than 50 ml/min/1.73 m2 should receive 150 mg nizatidine once each evening. Patients with creatinine clearances less than 20 ml/min/1.73 m2 should receive 150 mg nizatidine every other night.

AB - To test the hypothesis that renal insufficiency alters nizatidine disposition, we determined the pharmacokinetics of nizatidine and its major metabolite after a single oral dose in normal volunteers and patients with various degrees of renal dysfunction, after a single intravenous dose in normal volunteers and patients with severe renal failure and during hemodialysis. After intravenous administration the elimination half-life increased from 1.5 ± 0.2 hours in normal volunteers to 6.9 ± 3.3 hours in patients with renal failure. The plasma clearance decreased from 0.59 ± 0.07 L/kg/hr in normal volunteers to 0.14 ± 0.02 L/kg/hr in patients with renal failure. Nizatidine bioavailability was nearly 100% in normal volunteers but decreased to 75% in patients with renal failure. The volume of distribution was 1.3 ± 0.1 L/kg in normal volunteers and was not different in patients with renal failure. Nizatidine protein binding was about 30% in normal and uremic plasma. The drug was not substantially removed by hemodialysis. Patients with creatinine clearances less than 50 ml/min/1.73 m2 should receive 150 mg nizatidine once each evening. Patients with creatinine clearances less than 20 ml/min/1.73 m2 should receive 150 mg nizatidine every other night.

UR - http://www.scopus.com/inward/record.url?scp=0023909772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023909772&partnerID=8YFLogxK

M3 - Article

VL - 43

SP - 688

EP - 695

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -